Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Sponsor: AbbVie
Listed as NCT01441973, this PHASE2 trial focuses on Smoldering Multiple Myeloma and remains completed. Sponsored by AbbVie, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .